Recent Updates — ADRX

ADARx Pharmaceuticals closed its initial public offering on September 28, 2026, selling 26,250,000 shares at $17.00 per share for aggregate gross proceeds of approximately $446.3 million. Concurrently, the company completed a private placement with AbbVie Inc., issuing 5,255,542 shares to result in an approximate 4.9% ownership stake, generating roughly $89.3 million in gross proceeds. The company also filed an amended and restated certificate of incorporation and adopted new bylaws effective upon the IPO closing. ADARx Pharmaceuticals operates as a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders.